Navigation Links
febit Announces Strategic Investment and Technology Development Agreement With In-Q-Tel
Date:11/19/2008

Lexington, Mass., Nov. 19 /PRNewswire/ -- febit group, specialists in the field of advanced and flexible genomic analysis, today announced a strategic investment and technology development agreement with In-Q-Tel, the independent strategic investment firm that identifies innovative technology solutions to support the mission of the broader U.S. Intelligence Community.

This strategic collaboration will further the development of febit's Geniom(R) Technology to detect pathogens more quickly and with increased reliability. The technology development agreement with In-Q-Tel is anticipated to improve the sensitive, flexible, and fully automated Geniom platform for the multiplexed detection and classification of known and unknown pathogens for the special needs of bio security. The strategic investment is the result of an extensive evaluation process and thorough testing of febit's technology.

"febit's technology has the potential to become an important tool within the bio security sector," said Ben Levitan, Partner at In-Q-Tel. "We are excited about the capabilities of the existing platform and believe that our strategic collaboration with febit will lead to a well-engineered and practical high-end analysis device for multiple applications."

"This strategic investment in febit is In-Q-Tel's first engagement with a German company and validates febit's cutting-edge technology capabilities," said Professor Christof Hettich, member of febit's supervisory board and representative of its German lead investor Dievini GmbH & Co KG, the counsellors of the investment companies of Dietmar Hopp and family -- the co-founder and longstanding CEO of SAP.

"febit develops simple solutions for complex genomic tasks with an unsurpassed degree of automation. We are thrilled about the anticipated opportunities resulting from our agreement with In-Q-Tel," said Cord F. Staehler, CEO at febit. "febit's p
'/>"/>

SOURCE febit
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. The febit science lounge presents: Webinar About Role of Non-Protein-Coding RNA in Human Genome Set for 11 a.m. EDT on June 12
2. Elsevier announces launch of PM&R in partnership with the AAPM&R
3. Robert Wood Johnson Foundation Announces Grant Recipients for $18 Million Dollar Initiative to Prevent Intimate Partner Violence
4. URAC Announces Accreditation Standards for Comprehensive Wellness Programs
5. MDS Inc. Announces Appointment of James S.A. MacDonald as Chairman of Board of Directors
6. USA-ONE Interactive Announces Document Management Solutions That Meet the Needs of Individual Industries
7. Barr Announces Agreements on Nasacort(R) AQ, Allegra(R) D-12 and Allegra(R) Patent Challenges
8. Acumen Fund Announces New Investments In Pakistan To Build Scalable Business That Serve The Poor
9. QC Sciences™ Announces Innovative Solution to Reduce Laboratory Costs : The NuView System™ For Non-Gynecologic Cytology Affords Substantial Savings
10. Capella University Announces $50,000 in Scholarships to Graduate Students in Mental Health Services : Ten students are awarded scholarships at online university
11. Message Archiving Leader Privacy Networks Announces Free Anti-Spam Software to Businesses and Organizations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Today at the State Capitol, ... with the California Healthcare Institute (CHI) and the ... Assembly resolution recognizing Feb. 28, 2015 as Rare ... caring for millions of Californians living with nearly ... policy research organization, representing leading California academic institutions, ...
(Date:3/2/2015)... 02, 2015 Surgeons at the ... Allegheny Health Network, are exploring an innovative use ... Visual Info Zonal Reminder (VIZR), to assist in the ... Google Glass is a wearable technology with an optical ... format. Wearers communicate with the Internet via natural language ...
(Date:3/2/2015)... Ticket Down is a reputable source ... . This popular site has reduced all ticket prices ... for added savings. , Parrotheads in the Los Angeles ... headlining at the Hollywood Bowl for the first time ... October 22nd and it will be in conjunction with ...
(Date:3/2/2015)... Doctors in Novara, Italy have found that ... outcomes for people with mesothelioma than other clinical factors. ... new study on the Surviving Mesothelioma website. , ... Piedmont followed the cases of 172 mesothelioma patients ... fluid. , “Persistent lung expansion after pleural talc ...
(Date:3/2/2015)... Burns Engineering's Lab-to-Lab Calibration Service ... Standard Platinum Resistance Thermometers (SSPRTs) and industrial Resistance ... less . . . guaranteed. Their ... Code 200706-0), ISO 9001 and 17025 Certified and ... -196°C to 500°C, both ITS-90 and Callendar-van Dusen ...
Breaking Medicine News(10 mins):Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 3Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2
... Study may lead to new treatments for PTSD, researchers ... with stress-related psychiatric conditions have faulty circuitry in the ... new study suggests. , For the study, researchers presented ... patients, those with major depression and those with other ...
... and dental office,staff have realized the benefits of ... taken advantage of electronic predeterminations.,These electronic transactions may ... benefit information while the patient is still,in the ... "Paper submissions typically take 10 to 14 business ...
... starting school suffer from sleep disturbances and these may ... current edition of Deutsches rzteblatt International ( ... and adolescent psychiatrist Gerd Lehmkuhl and his colleagues present ... , The authors have as yet interviewed 1388 children ...
... , Montreal, December 3rd, 2008 A Canadian and ... from the Research Institute at the Montreal Children,s Hospital of ... Canadian Institutes of Health Research (CIHR) and the Foundation Fighting ... research project to develop innovative gene therapies for a number ...
... CINCINNATI A genetic malfunction that causes DNA instability ... put them at high risk for squamous cell carcinomas ... posted online ahead of print by Oncogene . ... report the breakdown of a cell signaling pathway for ...
... HLTH Corporation (Nasdaq: HLTH ) announced today ... 80,000,000 shares of its common stock at a price of $8.80 ... on November 25, 2008. As previously announced, HLTH exercised its ... extending the tender offer and has accepted for purchase 83,699,922 shares, ...
Cached Medicine News:Health News:Memory Formation Different in Those With Stress-Related Psychiatric Disorders 2Health News:Electronic Submission for Dental Predeterminations May Increase Efficiency, Patient Satisfaction 2Health News:CA$2.4 million toward gene therapy for human degenerative retinal diseases 2Health News:Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer 2Health News:Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer 3Health News:Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer 4Health News:HLTH Corporation Announces Final Results of Its Tender Offer 2Health News:HLTH Corporation Announces Final Results of Its Tender Offer 3
(Date:3/2/2015)... 2, 2015   Emerson Ecologics, LLC ... supplements, prescription products and natural health and ... with Anabolic Laboratories, a leading manufacturer of ... new partnership will allow Anabolic Laboratories to ... practitioner segments and provide customers with added ...
(Date:3/2/2015)... Conn., March 2, 2015  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... twelve months ended December 31, 2014. Fourth ... for Distribution and Reinvestment ("CAD" or "Cash Flow") of ... $58.0 million for the full year 2014;  , ...
(Date:3/2/2015)... CUPERTINO, Calif. , March 2, 2015 /PRNewswire/ ... announced its Epigenomic Regulator Program, and the successful ... the program,s lead product candidate DUR-928.  DUR-928 is ... may have broad applicability in metabolic diseases such ... steatohepatitis (NASH), and in acute organ injuries such ...
Breaking Medicine Technology:Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 2Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 3Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 2Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 3Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 4Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 5Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 6Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 7Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 8Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 9Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 10Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 11Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 12Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 13Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 14Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 15DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5
... Dec. 4 Long-term data published in,EuroIntervention showed ... (MVA),after repair with the MitraClip(R) system to correct ... mitral stenosis. Additionally,with two years of follow-up, none ... surgery for mitral stenosis. At 12 months no,important ...
... newly diagnosed patients with a life-threatening type of leukemia to be ... , - Exjade results at ASH to show benefits ... damage key organs , , - ... to report on optimal post-surgery treatment strategy, Femara vs. tamoxifen , ...
Cached Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22
... Medical® clear, all-silicone Foley catheters eliminate ... other Foley catheter designs. As an ... for creating a safe, dependable Foley ... Medical's all-silicone catheters will not leach ...
... Used for stone manipulation ... tract. Enhanced wire strength permits ... ureter more readily than standard ... facilitates easy, ergonomic one-handed operation. ...
... for soft-tissue repair, including, ... paravaginal repairs, such as ... Surgisis® ES is designed ... for intraoperative applications. Supplied ...
... Used to prevent ... allow renal drainage after ... in peel-open packages. Intended ... Periodic evaluation is advised; ...
Medicine Products: